A woman’s death after an unapproved NAD+ IV infusion highlights the dangers of unregulated longevity treatments and the gap between hype and evidence.
A tragic death linked to unregulated NAD+ infusions reveals the deadly risks of bypassing clinical trials in the pursuit of longevity.
The pursuit of longevity has become a booming industry, with clinics offering unproven therapies to those desperate to turn back the clock. But a recent tragedy underscores the potential deadly consequences of this unregulated market. A young woman died after receiving an intravenous NAD+ infusion at a non-medical spa, raising urgent questions about the safety and efficacy of such treatments.
The Tragic Case
In early 2025, a 32-year-old woman visited a wellness clinic offering NAD+ infusions, marketed as a way to boost energy, improve cognitive function, and slow aging. Shortly after the infusion, she experienced severe complications and later died. The practitioner was unlicensed, and the clinic was not subject to standard medical oversight. This case is not isolated; it reflects a growing trend of unregulated longevity interventions.
Expert Warnings
Dr. Matt Kaeberlein, a leading longevity researcher at the University of Washington, warns that such therapies are ‘dangerously premature.’ In a recent statement, he said, ‘We have no robust evidence that IV NAD+ infusions provide any benefit in humans, and we know from animal studies that high doses can be harmful, potentially accelerating tumor growth.’ His lab recently published a preprint showing that high-dose NAD+ supplementation may accelerate tumor growth in mice with precancerous lesions.
Dr. Andrea Maier, co-director of the Center for Healthy Longevity at the National University of Singapore, emphasizes the need for evidence-based approaches. ‘The desire for a quick fix is understandable, but shortcuts can be lethal. We must insist on rigorous clinical trials before these therapies are offered to the public.’
Dr. Evelyne Bischof, a longevity researcher, adds that ‘the marketing often outpaces the science. Consumers are being sold hope, not health.’
The Science Behind NAD+
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular metabolism and DNA repair. Levels decline with age, leading to interest in supplementation. However, the evidence for oral precursors like nicotinamide riboside is mixed. A March 2025 randomized controlled trial published in Nature Aging found no significant effect on muscle function or cognition in older adults. IV infusions bypass the digestive system, but their safety and efficacy remain unproven.
Regulatory Gaps
In January 2025, the FDA issued warning letters to multiple clinics for marketing IV NAD+ infusions without approved indications. However, enforcement is challenging. A survey by the American Academy of Anti-Aging Medicine found that 35% of respondents had used unproven longevity therapies without medical supervision. The case of the young woman was linked to an unlicensed practitioner in a non-medical spa setting, highlighting regulatory gaps that allow such practices to flourish.
Safe Alternatives
Despite the hype, evidence-based strategies for healthspan extension exist: regular exercise, a balanced diet, adequate sleep, and stress management. Dr. Kaeberlein notes that ‘the most effective interventions are still the boring ones. We need to invest in rigorous research to find what works.’
The interest in NAD+ supplementation stems from early animal studies showing lifespan extension in worms and mice. However, human trials have not replicated these results. The field of longevity medicine has seen similar hype cycles before—for example, resveratrol after 2003 studies and rapamycin in the 2010s. Each time, early excitement gave way to more nuanced understanding. The current NAD+ craze mirrors these patterns, with clinics offering unapproved treatments decades before proof of safety. The history of anti-aging interventions is littered with examples like human growth hormone, which was widely abused for anti-aging despite evidence of serious side effects such as joint pain and increased cancer risk. Only stringent regulation and long-term studies can prevent these cycles from recurring.
A February 2025 analysis in Science Translational Medicine reviewed 30 years of longevity trends and found that 90% of commercially promoted anti-aging supplements had no evidence of efficacy in humans. The pattern is consistent: a promising animal study generates buzz, clinics and direct-to-consumer companies rush to market, and regulators lag behind. The tragic death from NAD+ infusion is a stark reminder that when profit outpaces evidence, it is consumers who pay the price. Strengthening regulatory oversight for compounded IV therapies and requiring proof from randomized controlled trials before marketing could help close the gap between hope and data.
